AddLife (ALIF) Q2 2026 earnings summary

Executive summary

• Positive development across all business areas, with significant margin improvements and strong contributions from recent acquisitions.

• Sales, earnings, and operating cash flow showed consistent growth, driven by advanced products, organic momentum, and diligent improvement initiatives.

• Home Care and eye surgery segments demonstrated notable progress, reflecting long-term improvement efforts and targeted initiatives.

• Strong performance in Nordics, Eastern Europe, and research segments, despite headwinds in Spain and the UK.

• Profit after tax increased 30% in Q2 and 17% for H1, with EPS up to SEK 1.06 and SEK 2.11, respectively.

Financial highlights

• Group EBITA margin rose to 12.6% from 11.9% year-over-year, with EBITA up 11% to SEK 342m in Q2.

• Net sales reached SEK 2,721m in Q2 (+6%), with 4% organic and 3% acquired growth; H1 net sales SEK 5,366m (+2%).

• Profit before tax rose 29% year-over-year, driven by revenue growth and gross margin expansion.

• Operating cash flow increased to SEK 165m in Q2 (from SEK 119m), with LTM cash conversion around 100%.

• Equity ratio stable at 43%; net debt/equity ratio at 0.8.

Outlook and guidance

• Margin expansion and efficiency remain key priorities, with ongoing improvement initiatives and acquisition activity expected to support further growth.

• Market tailwinds in Homecare and advanced products expected to sustain positive momentum.

• Stable underlying growth and strong margins anticipated for H2 2026.

• Strong order book in the U.K. supports confidence in future capital goods sales despite current subdued market.

• Acquisition pipeline is robust, with more advanced-stage processes than last year.